Antibody Drug Conjugate Technologies

Hummingbird Bioscience and Synaffix Enter $150m License Agreement


Synaffix to provide Hummingbird Bioscience access to proprietary ADC technologies. Synaffix to receive up to $150m in upfront and milestone payments plus royalties.

Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, and Hummingbird Bioscience (Hummingbird Bio), a data-driven precision biotherapeutics company using its Rational Antibody Discovery (RAD) platform to discover and engineer antibodies against optimal yet elusive epitopes, thereby unlocking novel mechanisms of action, today announced that they entered into a licensing agreement that will enable Hummingbird Bio to develop a next generation ADC program using Synaffix technology.

We believe that, by combining Synaffix’s ADC technologies with our antibodies, we have the potential to create best-in-class ADCs.

Piers Ingram, Ph.D., CEO and co-founder of Hummingbird Bio

Deal structure includes royalties

Under the terms of the agreement, Synaffix will be eligible to receive up to $150 million, including upfront and milestone payments, plus royalties on net sales. For the target licensed, Hummingbird Bio is granted rights to utilize Synaffix proprietary ADC technologies GlycoConnect™ and HydraSpace™, in combination with select toxSYN™ linker-payloads.

$150m upfront and milestone payments